Akums Drugs and Pharmaceuticals

Akums Drugs reported a mixed Q1 FY26. CDMO revenue grew 4% YoY to ₹813 crore, but volumes were modest at 1%Current 1%. Reported change: +1% YoY. due to continued API price declines. EBITDA margins remained healthy at 14.7%, supported by better product mix. The company received 27 DCGI approvalsCurrent 27 DCGI approvals. Reported change: +27 vs FY25 full year 31. (vs 31 in all of FY25) and its first European dossier approval for rivaroxaban. API losses reduced by 50% YoYCurrent reported value: 50% YoY. No comparable prior figure is available in the source record.. Management guided for mid-single-digit CDMO growth in FY26, with the European contract (₹300 crCurrent ₹300 Cr. Reported change: New.ore annual revenue) starting April 2027. Risks include sustained API price weakness and slower-than-expected ramp-up in European exports.